WO2006000421A2 - Agent et produit alimentaire agissant contre l'ige - Google Patents

Agent et produit alimentaire agissant contre l'ige Download PDF

Info

Publication number
WO2006000421A2
WO2006000421A2 PCT/EP2005/006817 EP2005006817W WO2006000421A2 WO 2006000421 A2 WO2006000421 A2 WO 2006000421A2 EP 2005006817 W EP2005006817 W EP 2005006817W WO 2006000421 A2 WO2006000421 A2 WO 2006000421A2
Authority
WO
WIPO (PCT)
Prior art keywords
ige antibody
repressing
agent
cyclodextrin
foodstuff
Prior art date
Application number
PCT/EP2005/006817
Other languages
English (en)
Other versions
WO2006000421A3 (fr
Inventor
Keiji Terao
Daisuke Nakada
Original Assignee
Wacker-Chemie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wacker-Chemie Gmbh filed Critical Wacker-Chemie Gmbh
Publication of WO2006000421A2 publication Critical patent/WO2006000421A2/fr
Publication of WO2006000421A3 publication Critical patent/WO2006000421A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to an IgE antibody repressing agent and foodstuff. More particularly, it relates to IgE antibody repressing agent and foodstuff having an effect of ameliorating allergic diseases characterised in comprising alpha-cyclodextrin.
  • IgE immunoglobulin
  • mast cell membrane stabilisers or adrenocortical hormones are administered in a peroral way or in the form of a cream.
  • antihistamine agents exert side effects such as drowsiness or thirst and mast cell membrane stabilisers are not expected to produce an alleviating effect upon an already established disease.
  • side effects of adreno-cortical hormones include gastrointestinal troubles, liver troubles, diabetes, high blood pressure, etc. Furthermore, all these substances are applied for a temporary treatment and after the suspension of their administration a relapse may cause various problems .
  • a purified glucomannan is used containing at least 90% edible fibre obtained from Amorphophallus konjak (devil's tongue) powder, which is made easily soluble in water by grinding treatment. Since this material is produced from Amorphophallus konjak, it can also be used as a food.
  • Amorphophallus konjak devil's tongue
  • this material is produced from Amorphophallus konjak, it can also be used as a food.
  • the production of this IgE antibody repressing agent and food is quite laboursome, and it is therefore desirable to provide an IgE antibody repressing agent and foodstuff that are more easy to produce and safely consumable.
  • the problem to be solved in this invention is to provide an IgE antibody repressing agent or food having no side effect, and which are easy to produce and safely consumable.
  • alpha- cyclodextrin exhibits an IgE antibody repressing ability.
  • Alpha-cyclodextrin is a hardly digestible dextrin having an effect to reduce blood sugar level and reduce the amount of neutral lipids. It is marketed as functional food additive.
  • the authors of this invention obtained an IgE antibody repressing agent and food having the effect of ameliorating an IgE allergic condition.
  • wich comprises the following preferred embodiments (1) to (3) : (1) An IgE antibody repressing agent comprising alpha- cyclodextrin, wherein the allergic disease is bronchial asthma, atopic dermatitis or allergic nasal inflammation. (2) An IgE antibody repressing foodstuff having an effect of improving allergic diseases characterised in comprising alpha- cyclodextrin. (3) An IgE antibody repressing foodstuff according to said (2) wherein the allergic disease is bronchial asthma, atopic dermatitis or allergic nasal inflammation.
  • the IgE antibody repressing agent and foodstuff of this invention is efficacious for allergic diseases such as bronchial asthma, atopic dermatitis or allergic nasal inflammation. Since this IgE antibody repressing agent and food comprises alpha-cyclodextrin as active component that has been recognised as a functional food additive, their use is of high safety permitting a general and wide range application.
  • Alpha-cyclodextrin contained in the active component of this invention can be produced from natural substances such as maize, potato, etc.; particularly suitable is the inexpensive maize.
  • a commercially available ⁇ -cyclodextrin can also be used as ⁇ -cyclodextrin of this invention.
  • the IgE antibody repressing agent of this invention can be used in the form of powder, granule, capsule, chewable, tablet, etc.
  • generally applied additives can be admixed, such as starch, lactose, white sugar, mannitol, carboxymethyl cellulose, corn starch, inorganic salts, etc., in an appropriate formulation.
  • the daily intake amount of this IgE antibody repressing agent or food for an adult is preverably more than 100 mg without upper limit, more preferably 1 g to 100 g, most preferably 5 g to 15 g, expressed in terms of ⁇ - cyclodextrin content as active component.
  • the dose is preferably established in function of the health condition.
  • the intake can be done any time but, whenever possible, intake is suggested orally before sleeping or at the time or during meals in the morning, at noon or in the evening.
  • An IgE antibody repressing foodstuff of this invention includes foods in liquid, gel, sol, solid etc., form containing ⁇ -cyclodextrin.
  • a liquid foodstuff include mineral water, tea, sport drink, apple juice, orange juice, beer, wine, etc. beverages with dissolved ⁇ - cyclodextrin as an IgE antibody repressing drink.
  • a gel-form food can be an ⁇ -cyclodextrin containing solid jelly, tofu, egg tofu, etc.
  • a sol-form food can be an ⁇ -cyclodextrin containing liquid jelly or the like.
  • a solid form food can be rice, hulled products etc. obtained with ⁇ -cyclodextrin addition and processed to foodstuff, e.g. udon, soba, baked soba, noodles, macaroni, various breads, cereales, milk products, etc.
  • the invention further relates to a process for the production of an antiinflammatory active agent, preferred an antiallergic active agent, especially preferred an IgE Antibody Repressing Agent charcterised in that ⁇ -cyclodextrin is incorporated into foodstuff .
  • the incorporation is preferably done by mixing, dissolving or blending.
  • the invention further relates to the use of ⁇ -cyclodextrin as antiinflammatory active agent, preferred as antiallergic active agent, especially preferred as IgE Antibody Repressing Agent. For this purpose it is applied in the doses named above.
  • Example 1 Preparation of IgE antibody repressing agent
  • the IgE antibody repressing agent was CAVAMAX ® W6 Food grade (commercially available from Wacker-Chemie GmbH, Kunststoff) containing ⁇ -cyclodextrin produced from maize starch by enzymatic reaction.
  • this IgE antibody repressing agent was given in a daily dose of 5 to 15 g, directly or dissolved in water, etc., or mixed with rice etc. foods.
  • Example 2 Preparation of IgE antibody repressing food (1) CAVAMAX ® W6 Food grade containing ⁇ -cyclodextrin produced from maize starch by enzymatic reaction was dissolved in mineral water, tee, sport drink, apple juice, orange juice, beer, wine etc. beverages in an amount of 5g/100 mL so as to obtain an IgE antibody repressing beverage. (2) Further, ⁇ -cyclodextrin was combined with white rice or whole grained rice in an amount of 5 g for 0.18 litres to prepare an IgE antibody repressing rice food. Moreover, using this IgE antibody repressing rice, rice ball, risotto, curry rice, etc. foodstuffs were prepared.
  • Example 3 Test of antiinflamatory activity (1) Experimental method 5 g IgE antibody repressing agent produced in Example 1 was dissolved in 100 mL water and given to patients with bronchial asthma, atopic dermatitis or allergic nasal inflammation, daily, before meals, during a period of two months and the change in their health state was observed.
  • Example 4 Test of antiinflamatory activity As example of asthma healing, the history of a 47 years old fully recovered patient was as follows. Infantile asthma started in childhood, then he began to play baseball in the middle school and his asthma temporarily stopped. Asthma relapsed at the age of 36 and, from that time, broke out once in a month and, for ten years, became increasingly violent with the age. During that time, steroids, antibiotics, peroral antiphlogistics/antipyretics were adminis-tered. The IgE antibody repressing agent of the Example 1 of this invention was applied as described in Example 3 for two months. Though alcohol consumption and smoking were also interrupted before the experiment, asthmatic symptoms have completely disappeared. Thereafter, application was interrupted for half a year but symptoms did not reappear.
  • the IgE antibody repressing agent of this invention shows a high therapeutical effect for allergic diseases such as allergic nasal inflammation and the like. It can be expected that for patients with unclear effect a sustained application would bring amelioration or healing.
  • Table 1 Results with IgE antibody repressing agent
  • the IgE antibody repressing agent and food of this invention is effective for allergic diseases such as bronchial asthma, atopic dermatitis and allergic nasal inflammation.
  • These IgE antibody repressing agents and foodstuffs were found as safe functional foods and, since their active component is the inexpensive ⁇ -cyclodextrin available in great quantities, a highly economic and wide application has been made possible.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La présente invention concerne un agent et un produit alimentaire agissant en toute sécurité contre l'IgE et possédant un effet thérapeutique significatif. Lesdits agent et produit alimentaire agissant contre l'IgE et permettant de traiter les maladies allergiques associées à l'IgE contiennent de l'alpha-cyclodextrine comme composant actif.
PCT/EP2005/006817 2004-06-24 2005-06-23 Agent et produit alimentaire agissant contre l'ige WO2006000421A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004186898A JP2006008568A (ja) 2004-06-24 2004-06-24 ＩｇＥ抗体抑制剤および食品
JP2004-186898 2004-06-24

Publications (2)

Publication Number Publication Date
WO2006000421A2 true WO2006000421A2 (fr) 2006-01-05
WO2006000421A3 WO2006000421A3 (fr) 2006-04-13

Family

ID=34979676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006817 WO2006000421A2 (fr) 2004-06-24 2005-06-23 Agent et produit alimentaire agissant contre l'ige

Country Status (2)

Country Link
JP (1) JP2006008568A (fr)
WO (1) WO2006000421A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069530A (zh) * 2016-02-28 2018-12-21 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
US10525038B2 (en) 2011-01-11 2020-01-07 Dimerix Bioscience Pty Ltd. Combination therapy
WO2021001349A1 (fr) 2019-07-01 2021-01-07 Aquilon Pharmaceuticals Composition inhalable comprenant de la cyclodextrine destinée à être utilisée dans le traitement d'inflammations nasales
US11007157B2 (en) 2013-01-23 2021-05-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11166968B2 (en) * 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN115209746A (zh) * 2020-03-02 2022-10-18 株式会社环化生物 肠道功能改善剂
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12006298B2 (en) 2019-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655034A1 (fr) * 2004-10-10 2006-05-10 Université de Liège Utilisation d'un composé de cyclodextrine pour le traitement et la prévention des maladies inflammatoires bronchiques.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A2 (fr) * 1994-09-28 1996-05-01 Senju Pharmaceutical Co., Ltd. Suspension aqueuse nasale comprenant cyclodextrine
WO1996014838A1 (fr) * 1994-11-15 1996-05-23 Vivorx Pharmaceuticals, Inc. Nouvelles compositions contenant de la diacetyldapsone et leur utilisation pour traiter differentes maladies
US20030077316A1 (en) * 2001-04-02 2003-04-24 Jane Nichols Psoriasis patch
EP1348714A1 (fr) * 2002-03-25 2003-10-01 Council Of Scientific And Industrial Research Polypeptide utile comme agent antiallergénique/antiasthmatique, son procédé de préparation et compositions pharmaceutique contenant ce peptide et leur utilisation
WO2005053637A2 (fr) * 2003-11-26 2005-06-16 Astrazeneca Ab Nouveaux composes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54145268A (en) * 1978-05-04 1979-11-13 Tomoyasu Nakashima Beverage producing method
JPH0637388B2 (ja) * 1986-02-17 1994-05-18 千寿製薬株式会社 水性液剤
JPH0813257B2 (ja) * 1992-11-25 1996-02-14 日成興産株式会社 痩身用食品
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
JPH06225741A (ja) * 1993-02-02 1994-08-16 Kyokuto Internatl Corp 食品保存料及び食品の保存方法
JPH07115934A (ja) * 1993-10-22 1995-05-09 Hairu:Kk 痩身用食品
JPH07115935A (ja) * 1993-10-22 1995-05-09 Hairu:Kk 痩身用食品
JPH08151332A (ja) * 1994-09-28 1996-06-11 Senju Pharmaceut Co Ltd 点鼻用水性懸濁液
JP2001220355A (ja) * 2000-02-07 2001-08-14 Teijin Ltd ＰＰＡＲβ／δ及びγリガンドからなる肥満細胞活性化抑制剤
JP4180258B2 (ja) * 2001-08-06 2008-11-12 西川ゴム工業株式会社 ＩｇＥ抗体抑制剤および食品
WO2003074483A1 (fr) * 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A2 (fr) * 1994-09-28 1996-05-01 Senju Pharmaceutical Co., Ltd. Suspension aqueuse nasale comprenant cyclodextrine
WO1996014838A1 (fr) * 1994-11-15 1996-05-23 Vivorx Pharmaceuticals, Inc. Nouvelles compositions contenant de la diacetyldapsone et leur utilisation pour traiter differentes maladies
US20030077316A1 (en) * 2001-04-02 2003-04-24 Jane Nichols Psoriasis patch
EP1348714A1 (fr) * 2002-03-25 2003-10-01 Council Of Scientific And Industrial Research Polypeptide utile comme agent antiallergénique/antiasthmatique, son procédé de préparation et compositions pharmaceutique contenant ce peptide et leur utilisation
WO2005053637A2 (fr) * 2003-11-26 2005-06-16 Astrazeneca Ab Nouveaux composes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUNDUEANU G ET AL: "Preparation and characterization of starch/cyclodextrin bioadhesive microspheres as platform for nasal administration of Gabexate Mesylate (Foy<(>R)) in allergic rhinitis treatment" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 25, no. 1, January 2004 (2004-01), pages 159-170, XP004467246 ISSN: 0142-9612 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US10525038B2 (en) 2011-01-11 2020-01-07 Dimerix Bioscience Pty Ltd. Combination therapy
US11771664B2 (en) 2013-01-23 2023-10-03 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11701331B2 (en) 2013-01-23 2023-07-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11007157B2 (en) 2013-01-23 2021-05-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11166968B2 (en) * 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
CN116531400A (zh) * 2016-02-28 2023-08-04 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
CN109069530A (zh) * 2016-02-28 2018-12-21 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
EP3419633A4 (fr) * 2016-02-28 2019-10-30 Aldeyra Therapeutics, Inc. Traitement des pathologies oculaires allergiques avec des cyclodextrines
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11583529B2 (en) 2017-10-10 2023-02-21 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CN114269329A (zh) * 2019-07-01 2022-04-01 阿奎隆制药公司 用于治疗鼻部炎症的含环糊精的可吸入组合物
WO2021001349A1 (fr) 2019-07-01 2021-01-07 Aquilon Pharmaceuticals Composition inhalable comprenant de la cyclodextrine destinée à être utilisée dans le traitement d'inflammations nasales
BE1027425B1 (fr) * 2019-07-01 2021-02-08 Aquilon Pharmaceuticals Composition inhalable comprenant de la cyclodextrine a utiliser dans le traitement d’inflammations nasales
US12006298B2 (en) 2019-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN115209746A (zh) * 2020-03-02 2022-10-18 株式会社环化生物 肠道功能改善剂

Also Published As

Publication number Publication date
WO2006000421A3 (fr) 2006-04-13
JP2006008568A (ja) 2006-01-12

Similar Documents

Publication Publication Date Title
WO2006000421A2 (fr) Agent et produit alimentaire agissant contre l&#39;ige
US10111924B2 (en) Dietary supplement for the treatment of acid reflux and gastro-oesophageal reflux disease (GORD/GERD)
JP2009502958A (ja) ストレスの治療または管理の方法
US20030228393A1 (en) Multi-phase food &amp; beverage
US20010002269A1 (en) Multi-phase food &amp; beverage
CN104432084A (zh) 一种调理粉及其制备方法和用途
KR100278875B1 (ko) 과립화된 염기를 함유하는 실륨 음료 혼합 조성물
CN100546503C (zh) 苜蓿保健饮料
CN115777860A (zh) 一种西红花人参颗粒饮品、其制备方法和应用
US20030211176A1 (en) Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage
CN106578077A (zh) 一种含海带膳食纤维的奶茶及其制备方法
Smith et al. Dietary concerns associated with the use of medications
US20120189653A1 (en) Food/beverage and pharmaceutical composition for oral administration for improvement in acidic urine each comprising fucoidan as active ingredient
JP3489095B2 (ja) 健康食品及び健康飲料
JPH0987302A (ja) キトサンを含む組成物
KR101487769B1 (ko) 아스퍼질러스 오리재를 이용한 배변촉진용 또는 다이어트용 식품 조성물
JP3561764B2 (ja) 呼吸器系疾患治療薬
JP2000189109A (ja) 液状食品
CN111961560B (zh) 一种姜菊露酒及其制备方法
CN105876557A (zh) 一种葛根护肝饮料及其制作方法
WO2002007738A1 (fr) Combinaisons de chitosane et de psyllium permettant une adsorption synergique du triglyceride et du cholesterol
CN110074227A (zh) 一种凉茶饮配方及制备方法
KR102532514B1 (ko) 쓴메밀 추출물을 유효성분으로 함유하는 숙취해소용 조성물
US5601837A (en) Psyllium cholestyramine compositions with improved palatability
Van Heerden et al. If you drink alcohol, drink sensibly

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05754725

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase in:

Ref document number: PI0611587

Country of ref document: BR

Kind code of ref document: A2